Delivery Order SPE2DB20D1109-SPE2DB23FP19V
- Not listed
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Reyvow (100 mg tablet) and has a ceiling value of $1,527.15. It is a firm fixed-price contract with an ultimate completion date of May 12, 2025. The contract is not set-aside and is open to competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Reyvow 100 mg tablets, a prescription medication. The contract has a firm fixed price, a ceiling value of $1,695.27, and a period of performance ending on June 16, 2025. The contract is not set aside and was competitively awarded. AmerisourceBergen Drug Corp holds a significant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $2,520.77 firm-fixed-price contract is for the delivery of 4,566,211,365 units of the prescription medication Reyvow 100 mg tablets. The contract has an ultimate completion date of October 28, 2024 and does not include any set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of REYVOW 50 MG TABLET UD 8S. The delivery order, with a ceiling value of $1,094.01, is a firm fixed price contract with a completion date of May 13, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REYVOW 100 MG TABLET UD 8S, a pharmaceutical product, with a ceiling value of $1,549.05 and a performance period ending on May 7, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation for the supply of REYVOW 100 MG TABLET UD 8S, a pharmaceutical product. The award has a ceiling value of $1,061.36 and an ultimate completion date of September 19, 2024. The contract is a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts to provide a wide...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,226.31 firm fixed-price contract is for the supply of REYVOW 100 MG TABLET UD 8S, a pharmaceutical product. The contract has an ultimate completion date of October 25, 2022. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REYVOW 100 MG TABLET UD 8S, with a ceiling value of $1,621.89 and a completion date of June 17, 2025. The contract is a Firm Fixed Price (FFP) arrangement, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of REYVOW 100 MG TABLET UD 8S, a medication, with a ceiling value of $1,314.39 and a period of performance through June 13, 2025. The contract is not designated as a set-aside and is a firm fixed price delivery order. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,806.01, is for the delivery of REYVOW 50 MG TABLET UD 8S, a medication, to Conshohocken, PA. The contract has an ultimate completion date of May 28, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB23FP19VDelivery Order
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication Reyvow (100 mg tablets). The order has a ceiling value of $1,400.53 and a completion date of May 24, 2023. The contract is a firm fixed-price type and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as a primary vehicle for AmerisourceBergen to provide a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 5/23/23 |